NCT00836277View on ClinicalTrials.gov

Phase II Study of Irinotecan and Panitumumab

PHASE2CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Esophageal Cancer

Interventions

DRUG

Panitumumab

9mg/kg IV Day 1 Cycle = 21 days

DRUG

Irinotecan

125mg/m2 IV Day 1 and Day 8

Trial Locations (1)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

Weijing Sun, MD, FACP

OTHER